| scholarly article | Q13442814 |
| review article | Q7318358 |
| P2093 | author name string | Lakshmi A Devi | |
| Raphael Rozenfeld | |||
| Ittai Bushlin | |||
| P2860 | cites work | CB2 cannabinoid receptor activation produces antinociception by stimulating peripheral release of endogenous opioids | Q24556619 |
| Cannabidiol is an allosteric modulator at mu- and delta-opioid receptors | Q28298326 | ||
| Modulation of rat brain opioid receptors by cannabinoids | Q44347827 | ||
| Down-regulation of mu-opioid receptors in rat and monkey dorsal root ganglion neurons and spinal cord after peripheral axotomy | Q44347999 | ||
| Spinal opioid mu receptor expression in lumbar spinal cord of rats following nerve injury | Q44349026 | ||
| Inhibition of opioid-degrading enzymes potentiates delta9-tetrahydrocannabinol-induced antinociception in mice | Q44349438 | ||
| Expression of opioid receptors and c-fos in CB1 knockout mice exposed to neuropathic pain | Q44351361 | ||
| Synthesis and preliminary in vitro investigation of bivalent ligands containing homo- and heterodimeric pharmacophores at mu, delta, and kappa opioid receptors. | Q44351487 | ||
| Pre- and postsynaptic distribution of cannabinoid and mu opioid receptors in rat spinal cord | Q44351566 | ||
| Opioids and chronic neuropathic pain | Q44378990 | ||
| Upregulation of spinal cannabinoid-1-receptors following nerve injury enhances the effects of Win 55,212-2 on neuropathic pain behaviors in rats | Q44589971 | ||
| Loss of peripheral morphine analgesia contributes to the reduced effectiveness of systemic morphine in neuropathic pain | Q44725358 | ||
| Cannabinoid modulation of dynorphin A: correlation to cannabinoid-induced antinociception | Q44864213 | ||
| Dynorphin B and spinal analgesia: induction of antinociception by the cannabinoids CP55,940, Delta(9)-THC and anandamide | Q44869208 | ||
| Interactions between delta 9-tetrahydrocannabinol and kappa opioids in mice | Q45089121 | ||
| Involvement of dynorphin B in the antinociceptive effects of the cannabinoid CP55,940 in the spinal cord | Q45104730 | ||
| Behavioral, pharmacological and molecular characterization of the saphenous nerve partial ligation: a new model of neuropathic pain | Q46460752 | ||
| Induction of CB2 receptor expression in the rat spinal cord of neuropathic but not inflammatory chronic pain models | Q47808534 | ||
| Evidence for a bidirectional cross-tolerance between morphine and delta 9-tetrahydrocannabinol in mice | Q48087712 | ||
| Cannabinoid CB(1) receptor upregulation in a rat model of chronic neuropathic pain | Q48955227 | ||
| Chronic pain in individuals with spinal cord injury: a survey and longitudinal study. | Q51928815 | ||
| Analgesic Effects of Fatty Acid Amide Hydrolase Inhibition in a Rat Model of Neuropathic Pain | Q60679661 | ||
| Cannabinoid withdrawal syndrome is reduced in pre-proenkephalin knock-out mice | Q73315808 | ||
| Pronociceptive actions of dynorphin maintain chronic neuropathic pain | Q73550448 | ||
| mu opioid and CB1 cannabinoid receptor interactions: reciprocal inhibition of receptor signaling and neuritogenesis | Q28591542 | ||
| International Union of Pharmacology. XXVII. Classification of cannabinoid receptors | Q29616832 | ||
| Pharmacological and biochemical interactions between opioids and cannabinoids. | Q33677066 | ||
| Opioid-induced tolerance and dependence in mice is modulated by the distance between pharmacophores in a bivalent ligand series | Q34244966 | ||
| Participation of the opioid system in cannabinoid-induced antinociception and emotional-like responses | Q34543472 | ||
| Synergistic and additive interactions of the cannabinoid agonist CP55,940 with mu opioid receptor and alpha2-adrenoceptor agonists in acute pain models in mice. | Q35048705 | ||
| Site-specific increases in peripheral cannabinoid receptors and their endogenous ligands in a model of neuropathic pain. | Q35600288 | ||
| Synergistic interactions between cannabinoid and opioid analgesics | Q35620905 | ||
| Molecular and cellular basis of cannabinoid and opioid interactions. | Q36145933 | ||
| Efficacy and safety of opioid agonists in the treatment of neuropathic pain of nonmalignant origin: systematic review and meta-analysis of randomized controlled trials | Q36171579 | ||
| Chronic neuropathic pain: mechanisms, drug targets and measurement | Q36772936 | ||
| Advances in the field of cannabinoid--opioid cross-talk | Q37164808 | ||
| Targeting fatty acid amide hydrolase (FAAH) to treat pain and inflammation | Q37382150 | ||
| Interaction of the cannabinoid and opioid systems in the modulation of nociception | Q37444813 | ||
| The CB1 cannabinoid receptor can sequester G-proteins, making them unavailable to couple to other receptors | Q38319183 | ||
| Molecular mechanisms involved in the asymmetric interaction between cannabinoid and opioid systems | Q39363705 | ||
| The mu-opioid receptor agonist morphine, but not agonists at delta- or kappa-opioid receptors, induces peripheral antinociception mediated by cannabinoid receptors | Q40309006 | ||
| Recent advances in molecular recognition and signal transduction of active peptides: receptors for opioid peptides | Q41041826 | ||
| Central antinociception induced by mu-opioid receptor agonist morphine, but not delta- or kappa-, is mediated by cannabinoid CB1 receptor | Q41782285 | ||
| Regulation of opioid binding sites in the superficial dorsal horn of the rat spinal cord following loose ligation of the sciatic nerve: comparison with sciatic nerve section and lumbar dorsal rhizotomy | Q41906646 | ||
| Independence of, and interactions between, cannabinoid and opioid signal transduction pathways in N18TG2 cells | Q42461152 | ||
| Chronic administration of cannabinoids regulates proenkephalin mRNA levels in selected regions of the rat brain | Q42541382 | ||
| Modulation of rat brain cannabinoid receptors after chronic morphine treatment | Q42546895 | ||
| delta-9-Tetrahydrocannabinol increases prodynorphin and proenkephalin gene expression in the spinal cord of the rat. | Q42548403 | ||
| delta 9-Tetrahydrocannabinol increases proopiomelanocortin gene expression in the arcuate nucleus of the rat hypothalamus | Q42549900 | ||
| Changes in opioid and cannabinoid receptor protein following short-term combination treatment with delta(9)-tetrahydrocannabinol and morphine | Q43548271 | ||
| Motivational effects of cannabinoids are mediated by mu-opioid and kappa-opioid receptors. | Q43875647 | ||
| Cannabinoid withdrawal syndrome is reduced in double mu and delta opioid receptor knockout mice. | Q44282777 | ||
| Suppression of the morphine-induced rewarding effect and G-protein activation in the lower midbrain following nerve injury in the mouse: involvement of G-protein-coupled receptor kinase 2. | Q44283549 | ||
| Mu opioid receptors and analgesia at the site of a peripheral nerve injury | Q44325280 | ||
| Effects of sciatic nerve injuries on delta -opioid receptor and substance P immunoreactivities in the superficial dorsal horn of the rat. | Q44330623 | ||
| Reduction of stress-induced analgesia but not of exogenous opioid effects in mice lacking CB1 receptors | Q44330713 | ||
| Association of kappa opioid receptor mRNA upregulation in dorsal root ganglia with mechanical allodynia in mice following nerve injury | Q44333065 | ||
| Spinal administration of a delta opioid receptor agonist attenuates hyperalgesia and allodynia in a rat model of neuropathic pain | Q44333270 | ||
| Ultrastructural localization of the CB1 cannabinoid receptor in mu-opioid receptor patches of the rat Caudate putamen nucleus. | Q44334367 | ||
| Bilateral and differential changes in spinal mu, delta and kappa opioid binding in rats with a painful, unilateral neuropathy | Q44334608 | ||
| CB1-cannabinoid and mu-opioid receptor co-localization on postsynaptic target in the rat dorsal horn | Q44337088 | ||
| Influences of surgical decompression on the dorsal horn after chronic constriction injury: changes in peptidergic and delta-opioid receptor (+) nerve terminals | Q44340022 | ||
| Local peripheral opioid effects and expression of opioid genes in the spinal cord and dorsal root ganglia in neuropathic and inflammatory pain | Q44341214 | ||
| Expression of mu- and kappa-, but not delta-, opioid receptor mRNAs is enhanced in the spinal dorsal horn of the arthritic rats | Q44342268 | ||
| Effects of peripheral nerve ligation on expression of mu-opioid receptor in sensory ganglion neurons: an immunohistochemical study in dorsal root and nodose ganglion neurons of the rat. | Q44343652 | ||
| Inflammation of the hind limb as a model of unilateral, localized pain: influence on multiple opioid systems in the spinal cord of the rat. | Q44345359 | ||
| Enhancement of dynorphin gene expression in spinal cord following experimental inflammation: stimulus specificity, behavioral parameters and opioid receptor binding. | Q44345363 | ||
| Effects of peripheral nerve injury on delta opioid receptor (DOR) immunoreactivity in the rat spinal cord | Q44345463 | ||
| Compartment-specific localization of cannabinoid 1 (CB1) and mu-opioid receptors in rat nucleus accumbens | Q44345871 | ||
| Rapid upregulation of mu opioid receptor mRNA in dorsal root ganglia in response to peripheral inflammation depends on neuronal conduction | Q44347099 | ||
| P433 | issue | 1 | |
| P921 | main subject | cannabinoids | Q422936 |
| opioid | Q427523 | ||
| neuropathic pain | Q2798704 | ||
| P304 | page(s) | 80-86 | |
| P577 | publication date | 2009-10-25 | |
| P1433 | published in | Current Opinion in Pharmacology | Q3007702 |
| P1476 | title | Cannabinoid-opioid interactions during neuropathic pain and analgesia | |
| P478 | volume | 10 |
| Q48026611 | A multicentre, open-label, follow-on study to assess the long-term maintenance of effect, tolerance and safety of THC/CBD oromucosal spray in the management of neuropathic pain |
| Q38646883 | Age dependent plasticity in endocannabinoid modulation of pain processing through postnatal development |
| Q57058269 | Brain permeant and impermeant inhibitors of fatty-acid amide hydrolase synergize with the opioid analgesic morphine to suppress chemotherapy-induced neuropathic nociception without enhancing effects of morphine on gastrointestinal transit |
| Q38243708 | Cannabinoids for neuropathic pain |
| Q38503842 | Comprehensive Review of Medicinal Marijuana, Cannabinoids, and Therapeutic Implications in Medicine and Headache: What a Long Strange Trip It's Been …. |
| Q36438816 | Delta opioid receptor analgesia: recent contributions from pharmacology and molecular approaches |
| Q34524896 | Dimerization with cannabinoid receptors allosterically modulates delta opioid receptor activity during neuropathic pain |
| Q37680038 | Disease-specific heteromerization of G-protein-coupled receptors that target drugs of abuse |
| Q48298041 | Effects of centrally administered endocannabinoids and opioids on orofacial pain perception in rats |
| Q36655914 | Effects of daily delta-9-tetrahydrocannabinol treatment on heroin self-administration in rhesus monkeys |
| Q44342705 | Exploring the first Rimonabant analog-opioid peptide hybrid compound, as bivalent ligand for CB1 and opioid receptors |
| Q47570053 | Frequency of Cannabis Use Among Primary Care Patients in Washington State |
| Q37686142 | G-protein-coupled heteromers: regulation in disease |
| Q34360705 | Impact of efficacy at the μ-opioid receptor on antinociceptive effects of combinations of μ-opioid receptor agonists and cannabinoid receptor agonists |
| Q37998313 | Inhibiting the breakdown of endogenous opioids and cannabinoids to alleviate pain |
| Q39762143 | Interactions between cannabinoid receptor agonists and mu opioid receptor agonists in rhesus monkeys discriminating fentanyl |
| Q41572995 | Interactions between the Kynurenine and the Endocannabinoid System with Special Emphasis on Migraine |
| Q36852576 | Interactions between μ-opioid receptor agonists and cannabinoid receptor agonists in rhesus monkeys: antinociception, drug discrimination, and drug self-administration. |
| Q34674584 | Involvement of opioid system in antidepressant-like effect of the cannabinoid CB1 receptor inverse agonist AM-251 after physical stress in mice. |
| Q28468583 | Irish general practitioner attitudes toward decriminalisation and medical use of cannabis: results from a national survey |
| Q52584175 | New York Physicians' Perspectives and Knowledge of the State Medical Marijuana Program. |
| Q39650214 | New ursane triterpenoids from Ficus pandurata and their binding affinity for human cannabinoid and opioid receptors |
| Q33674800 | Oligomerization of G-protein-coupled receptors: a reality |
| Q42406036 | Opioid and cannabinoid synergy in a mouse neuropathic pain model |
| Q27004306 | Opioid receptor heteromers in analgesia |
| Q34624142 | Opioid-induced down-regulation of RGS4: role of ubiquitination and implications for receptor cross-talk |
| Q55333056 | Patterns of medicinal cannabis use, strain analysis, and substitution effect among patients with migraine, headache, arthritis, and chronic pain in a medicinal cannabis cohort. |
| Q44338917 | Peripheral interactions between cannabinoid and opioid receptor agonists in a model of inflammatory mechanical hyperalgesia |
| Q42158814 | Prescribing cannabis for harm reduction |
| Q47844005 | Psychiatric morbidity in ketamine users attending counselling and youth outreach services |
| Q27310866 | Receptor heteromerization expands the repertoire of cannabinoid signaling in rodent neurons |
| Q42411070 | Salvinorin A reduces mechanical allodynia and spinal neuronal hyperexcitability induced by peripheral formalin injection |
| Q47344641 | Slowly Signaling G Protein-Biased CB2 Cannabinoid Receptor Agonist LY2828360 Suppresses Neuropathic Pain with Sustained Efficacy and Attenuates Morphine Tolerance and Dependence |
| Q93189553 | State marijuana laws and opioid overdose mortality |
| Q90359017 | Targeting Cannabinoid 1 and Delta Opioid Receptor Heteromers Alleviates Chemotherapy-Induced Neuropathic Pain |
| Q35563620 | The Medicinal Cannabis Treatment Agreement: Providing Information to Chronic Pain Patients Through a Written Document |
| Q35400738 | The delta opioid receptor: an evolving target for the treatment of brain disorders |
| Q38664916 | The design of multitarget ligands for chronic and neuropathic pain |
| Q24601890 | The endocannabinoid system, cannabinoids, and pain |
Search more.